This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Université Paris-Saclay, Imperial College Innovations Limited, Institut Pasteur. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 102 
1 out of 174 
1 out of 898 
Years Active: 2021-2025
Title: Innovations of Pablo Guardado-Calvo in Dengue Virus Research
Introduction
Pablo Guardado-Calvo is a notable inventor based in Paris, France. He has made significant contributions to the field of virology, particularly in the development of anti-dengue vaccines and antibodies. His innovative work has led to the filing of two patents that focus on the Dengue virus Envelope Dimer Epitope (EDE).
Latest Patents
Guardado-Calvo's latest patents include groundbreaking research on anti-dengue vaccines and antibodies. The patents detail a Dengue virus Envelope Dimer Epitope (EDE) that spans the polypeptides of a Dengue virus Envelope polypeptide dimer. The EDE is presented on a dimer of Envelope proteins and is formed from consecutive or non-consecutive residues of the envelope polypeptide dimer. This dimer can be a homodimer or heterodimer of native and/or mutant envelope polypeptides from any one or two of DENV-1, DENV-2, DENV-3, and DENV-4. The EDE may also be a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, which is covalently stabilized with at least one disulphide inter-chain bond between the two sE monomers. Additionally, it can be stabilized through various methods, including sulfhydryl-reactive crosslinkers and modified sugars. The invention also includes compounds, such as antibodies or antibody fragments, that can neutralize more than one Dengue virus serotype.
Career Highlights
Throughout his career, Guardado-Calvo has worked with prestigious institutions, including Université Paris-Saclay and Imperial College Innovations Limited. His research has been pivotal in advancing the understanding of dengue virus and developing effective vaccines.
Collaborations
Some of his notable coworkers include Juthathip Mongkolsapaya and Alexander Rouvinski. Their collaborative efforts have contributed to the success of his research initiatives.
Conclusion
Pablo Guardado-Calvo's innovative work in the field of dengue virus research has led to significant advancements in vaccine development. His contributions are vital in the ongoing fight against dengue fever, showcasing the importance of research and innovation in public health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile